Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Among adults with endocarditis caused by 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴, 𝘌. 𝘧𝘢𝘦𝘤𝘢𝘭𝘪𝘴, or streptococcus species, tailored-duration antibiotic therapy led to 13 more days alive without antibiotics than standard therapy, but with a higher incidence of relapse. Full POET II trial results: #ESCCongress | European Society of Cardiology

NEJM

1,036,234 subscribers

20,654 views • 16 days ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

1 Comments

Charts.md15 days ago

England NHS (All Diagnoses) - I33.0: Acute and subacute infective endocarditis

Related Videos

In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: #ESCCongress | European Society of Cardiology

In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: #ESCCongress | European Society of Cardiology

NEJM

16,284 views • 17 days ago

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,384 views • 4 months ago

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

NEJM

15,621 views • 5 months ago

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:

NEJM

12,724 views • 2 months ago

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

NEJM

13,473 views • 7 months ago

Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. Full phase 3 REPLENISH trial results and Research Summary:

Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. Full phase 3 REPLENISH trial results and Research Summary:

NEJM

21,492 views • 29 days ago

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage, but is it really better than standard care with blood components? NEJM Editorial Fellow Katerina Lin, MD, recaps the results of the SWiFT trial. Read the full trial results:

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage, but is it really better than standard care with blood components? NEJM Editorial Fellow Katerina Lin, MD, recaps the results of the SWiFT trial. Read the full trial results:

NEJM

19,223 views • 26 days ago

Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results:

Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results:

NEJM

18,013 views • 2 months ago

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. Full trial results and Research Summary:

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. Full trial results and Research Summary:

NEJM

15,115 views • 5 months ago

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

NEJM

50,351 views • 1 year ago

60-Second Journal Club: NEJM Editorial Fellow Sarah Gorey, MB, summarizes the REDOX trial assessing hospitalization and mortality among patients with chronic severe hypoxemia who received long-term oxygen therapy for either 24 or 15 hours per day. Full trial:

60-Second Journal Club: NEJM Editorial Fellow Sarah Gorey, MB, summarizes the REDOX trial assessing hospitalization and mortality among patients with chronic severe hypoxemia who received long-term oxygen therapy for either 24 or 15 hours per day. Full trial:

NEJM

18,799 views • 1 year ago

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

NEJM

18,771 views • 8 months ago

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results and Research Summary:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results and Research Summary:

NEJM

34,365 views • 1 month ago

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,811 views • 1 year ago

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

NEJM

12,312 views • 6 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

NEJM

88,503 views • 1 year ago

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

NEJM

46,802 views • 10 months ago

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

NEJM

32,419 views • 9 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,843 views • 8 months ago

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

NEJM

12,265 views • 6 months ago